Register by Friday, May 27 & Save up to $800


Welcome to the 3rd Epigenetic–Targeted Drug Discovery & Development Summit

Taking place in person for the first time this summer, the 3rd Annual Epigenetic-Targeted Drug Discovery & Development Summit is the first and only devoted industry-specific forum exclusively focused on showcasing the latest research and pre-clinical and translational development of small-molecule, and other epigenetic modulators of gene expression, whilst providing pivotal insights to kickstart the next generation of clinically defining therapeutics and help overcome early-stage clinical trial challenges.

Attendees can expect to hear the latest discovery, preclinical and translational advancements in therapeutic interventions targeting all areas of epigenetic machinery including DNA methylation, histone post-translational modifications, chromatin remodeling, and non-coding RNAs (ncRNAs).

Access the full event guide to learn more.

2022 World-Class Speaker Faculty:

Asad Taherbhoy

Director of Drug Discovery

Foghorn Therapeutics

Alejandra Raimondi

Vice President Biological Sciences


David Bumcrot

Chief Scientific Officer

CAMP4 Therapeutics

Paloma Cejas

Assistant Director for Center for Functional Cancer Epigenetics

Dana-Farber Cancer Institute

Peter Atadja

Co-Founder & Chief Scientific Officer

K36 Therapeutics